Lexeo Therapeutics (LXEO)
Develops genetic medicines for inherited cardiovascular disease and select CNS disorders.
Something off on this page? Send us feedback.
Focused on pre-commercial AAV gene therapies, with lead work in Friedreich ataxia cardiomyopathy and PKP2-associated arrhythmogenic cardiomyopathy. The business depends on clinical success, regulatory approval, manufacturing readiness, and eventual commercialization.
Develops investigational AAV gene therapies for genetically defined cardiovascular diseases and a smaller CNS program. Lead candidate LX2006 delivers a functional FXN gene for Friedreich ataxia cardiomyopathy, while LX2020 targets PKP2-associated arrhythmogenic cardiomyopathy.
Earlier cardiac work includes LX2021 for desmoplakin cardiomyopathy and LX2022 for TNNI3-associated hypertrophic cardiomyopathy. LX1020 applies APOE2 delivery and APOE4 suppression in an APOE4-associated Alzheimer's disease program.
Retains exclusive worldwide development and commercialization rights to its candidates, with operations run from New York and a clinical-development-heavy workforce. The business depends on completing trials, obtaining approval, manufacturing readiness, and commercialization.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jan 13, 2026 | H.C. Wainwright | Target | Target: $13 | Target: $10 |
| Dec 17, 2025 | Raymond James | Target | Target: — | Target: $25 |
| Dec 10, 2025 | Oppenheimer | Target | Target: — | Target: $20 |
| Nov 20, 2025 | Cantor Fitzgerald | Target | Target: — | Target: $19 |
| Oct 21, 2025 | H.C. Wainwright | Target | Target: $15 | Target: $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $211.7M · Total debt $6.8M · Total assets $254.9M · Shareholders' equity $235.1M
- Revenue
- $0
- Operating income
- −$28.0M
- Net income
- −$25.9M
No dividends on record.
| Institutions | ≈ 107.73% | 88.39M shares | |
|---|---|---|---|
| 146 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.17% | 963.8K shares | |
| 9 holders · as of Aug 19, 2026 | |||
| Strategic holders | 8.89% | 7.29M shares | |
| 1 holder · as of Dec 8, 2025 | |||
| Adds to | 117.79% | ||
82.05M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 117.79%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Janus Henderson Group PLCStrategic | 8.89% | 7.29M | filed Dec 8, 2025 |
Suvretta Capital Management, LLCInstitution | 7.78% | 6.38M | as of Jun 30, 2026 |
Affinity Asset Advisors, LLCInstitution | 7.08% | 5.81M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.00% | 5.74M | as of Jun 30, 2026 |
Ra Capital Management, L.P.Institution | 6.09% | 5.00M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Jose Manuel Otero | officer: Chief Operating Officer | −1,304 | $4.96 |
| Aug 18, 2026 | Richard Nolan Townsend | director, officer: Chief Executive Officer | −3,345 | $4.95 |
| Aug 18, 2026 | Louis Edward Tamayo | officer: Chief Financial Officer | −4,117 | $4.91 |
| Jul 1, 2026 | Richard Nolan Townsend | director, officer: Chief Executive Officer | −25,947 | $4.48 |
| Jul 1, 2026 | Narinder Pal Bhalla | officer: Chief Medical Officer | −22,306 | $4.42 |
- Rocket Pharmaceuticals
AAV cardiovascular gene therapy peer in PKP2, Danon, and BAG3 programs
- Tenaya Therapeutics
Cardiac gene therapy peer with PKP2 and MYBPC3 cardiomyopathy programs
- Solid Biosciences
FA and cardiac genetic-medicine pipeline using AAV gene therapy
- Voyager Therapeutics
FXN gene-replacement program for Friedreich ataxia with Neurocrine
- Biogen
Approved Friedreich ataxia therapy owner through SKYCLARYS
- Intellia Therapeutics
One-time in vivo gene editing program for ATTR cardiomyopathy
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lexeo Therapeutics | $4.07 | −0.25% | $320.4M | — | — | — | — |
| Rocket Pharmaceuticals | $3.37 | +2.91% | $357.1M | — | — | — | — |
| Tenaya Therapeutics | $0.6901 | +2.42% | $146.2M | — | — | 109.5 | — |
| Solid Biosciences | $8.89 | +4.10% | $840.8M | — | — | — | — |
| Voyager Therapeutics | $3.13 | +1.63% | $186.1M | — | — | 5.4 | −39.1% |
| Biogen | $225.69 | +3.02% | $32.37B | 38.8 | 17.0 | 3.3 | +3.4% |
| Intellia Therapeutics | $12.71 | +3.97% | $1.71B | — | — | 28.7 | −46.2% |
| Median | 38.8 | 17.0 | 17.0 | −39.1% |